Verification evidence is still being completed.
PDF / print export
PolTREG S.A.
Gdansk, Poland
- Verified lead
- Piotr Trzonkowski
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- T-Regulatory Cell Therapy, Type 1 Diabetes, and Multiple Sclerosis
- Review cycle
- 24 April 2026
- Full address
- ul. Botaniczna 20, 80-298 Gdansk, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- PolTREG About Us page naming Prof. Piotr Trzonkowski as CEO and Co-founder.
- Editorial note
- Gdansk WSE-listed (PTG) clinical-stage cell-therapy biotech with named co-founder CEO, GMP Treg manufacturing, and T1D and MS clinical programs.
T-Regulatory Cell Therapy, Type 1 Diabetes, and Multiple Sclerosis
GMP Treg manufacturing, WSE PTG listing, Public CEO disclosure
Gdansk WSE-listed (PTG) clinical-stage cell-therapy biotech with named co-founder CEO, GMP Treg manufacturing, and T1D and MS clinical programs.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Gdansk, Poland
PolTREG S.A.
T-Regulatory Cell Therapy, Type 1 Diabetes, and Multiple Sclerosis · GMP cell-therapy manufacturing
Verified 24 Apr 2026 · 3 sources
Cell TherapyClinical
Gdansk WSE-listed (PTG) clinical-stage cell-therapy biotech with named co-founder CEO, GMP Treg manufacturing, and T1D and MS clinical programs.
Contact & location
- Website
- poltreg.com
- Company page
- Lead
- Piotr Trzonkowski (verified ↗)
- Compliance
- GMP Treg manufacturing
- Last reviewed
- 24 Apr 2026 (2mo ago)
- Scale
- GMP cell-therapy manufacturing
- Capabilities
- GMP Treg Cell Manufacturing · T1D and MS Clinical Programs · Proprietary Treg Expansion Processes
- Founded
- 2015
- Headcount
- 51-200
T-Regulatory Cell Therapy, Type 1 Diabetes, and Multiple Sclerosis
Gdansk WSE-listed (PTG) clinical-stage cell-therapy biotech with named co-founder CEO, GMP Treg manufacturing, and T1D and MS clinical programs.
Editorial note
PolTREG anchors Polish cell-therapy development with a named co-founder CEO, a GMP Treg manufacturing facility, Warsaw Stock Exchange listing since 2021, and clinical programs in Type 1 diabetes and multiple sclerosis.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Verification details
Clinical profileSTATUS: VERIFIED APRIL 2026
Piotr Trzonkowski
Chief Executive Officer and Co-Founder
Full addressul. Botaniczna 20, 80-298 Gdansk, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
GMP cell-therapy manufacturing
Gdansk, Poland. T-Regulatory Cell Therapy, Type 1 Diabetes, and Multiple Sclerosis. Review completed on 24 Apr 2026.
Polish Office for Registration of Medicinal Products, EMA, and WSE regulatory oversight
GMP Treg manufacturing, WSE PTG listing, Public CEO disclosure
Capabilities
GMP Treg Cell Manufacturing
T1D and MS Clinical Programs
Proprietary Treg Expansion Processes
Sources
The official sources used to verify this profile.
Infrastructure
Treg expansion manufacturing suites
Clinical trial operations
Cell-therapy analytics
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
Frequently asked questions
- Where is PolTREG S.A. located?
- PolTREG S.A. operates from ul. Botaniczna 20, 80-298 Gdansk, Poland, Gdansk, Poland.
- Who runs PolTREG S.A.?
- PolTREG S.A. is led by Piotr Trzonkowski, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What certifications does PolTREG S.A. hold?
- PolTREG S.A. is documented under GMP Treg manufacturing.
- What does PolTREG S.A. do?
- Gdansk WSE-listed (PTG) clinical-stage cell-therapy biotech with named co-founder CEO, GMP Treg manufacturing, and T1D and MS clinical programs. Core capabilities: GMP Treg Cell Manufacturing, T1D and MS Clinical Programs, Proprietary Treg Expansion Processes.
Editorial context
Related technical briefs
Briefs that name Gdansk as a covered market or city.